198 related articles for article (PubMed ID: 37782515)
1. Harmonizing Definitions for Progression Independent of Relapse Activity in Multiple Sclerosis: A Systematic Review.
Müller J; Cagol A; Lorscheider J; Tsagkas C; Benkert P; Yaldizli Ö; Kuhle J; Derfuss T; Sormani MP; Thompson A; Granziera C; Kappos L
JAMA Neurol; 2023 Nov; 80(11):1232-1245. PubMed ID: 37782515
[TBL] [Abstract][Full Text] [Related]
2. How patients with multiple sclerosis acquire disability.
Lublin FD; Häring DA; Ganjgahi H; Ocampo A; Hatami F; Čuklina J; Aarden P; Dahlke F; Arnold DL; Wiendl H; Chitnis T; Nichols TE; Kieseier BC; Bermel RA
Brain; 2022 Sep; 145(9):3147-3161. PubMed ID: 35104840
[TBL] [Abstract][Full Text] [Related]
3. Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials.
Kappos L; Wolinsky JS; Giovannoni G; Arnold DL; Wang Q; Bernasconi C; Model F; Koendgen H; Manfrini M; Belachew S; Hauser SL
JAMA Neurol; 2020 Sep; 77(9):1132-1140. PubMed ID: 32511687
[TBL] [Abstract][Full Text] [Related]
4. Real-world evidence of ocrelizumab-treated relapsing multiple sclerosis cohort shows changes in progression independent of relapse activity mirroring phase 3 trials.
Ingwersen J; Masanneck L; Pawlitzki M; Samadzadeh S; Weise M; Aktas O; Meuth SG; Albrecht P
Sci Rep; 2023 Sep; 13(1):15003. PubMed ID: 37696848
[TBL] [Abstract][Full Text] [Related]
5. Risk of secondary progressive multiple sclerosis after early worsening of disability.
Dzau W; Sharmin S; Patti F; Izquierdo G; Eichau S; Prat A; Girard M; Duquette P; Onofrj M; Lugaresi A; Ozakbas S; Gerlach O; Boz C; Grammond P; Terzi M; Amato MP; La Spitaleri D; Ramo-Tello C; Maimone D; Cartechini E; Buzzard K; Skibina O; van der Walt A; Butzkueven H; Iuliano G; Soysal A; Kalincik T
J Neurol Neurosurg Psychiatry; 2023 Dec; 94(12):984-991. PubMed ID: 37414538
[TBL] [Abstract][Full Text] [Related]
6. The impact of relapse definition and measures of durability on MS clinical trial outcomes.
Satyanarayan S; Cutter G; Krieger S; Cofield S; Wolinsky JS; Lublin F
Mult Scler; 2023 Apr; 29(4-5):568-575. PubMed ID: 37119208
[TBL] [Abstract][Full Text] [Related]
7. Defining progression independent of relapse activity (PIRA) in adult patients with relapsing multiple sclerosis: A systematic review
Sharrad D; Chugh P; Slee M; Bacchi S
Mult Scler Relat Disord; 2023 Oct; 78():104899. PubMed ID: 37499338
[TBL] [Abstract][Full Text] [Related]
8. Multiple Sclerosis Progression and Relapse Activity in Children.
Iaffaldano P; Portaccio E; Lucisano G; Simone M; Manni A; Guerra T; Paolicelli D; Betti M; De Meo E; Pastò L; Razzolini L; Rocca MA; Ferrè L; Brescia Morra V; Patti F; Zaffaroni M; Gasperini C; De Luca G; Ferraro D; Granella F; Pozzilli C; Romano S; Gallo P; Bergamaschi R; Coniglio MG; Lus G; Vianello M; Banfi P; Lugaresi A; Totaro R; Spitaleri D; Cocco E; Di Palma F; Maimone D; Valentino P; Torri Clerici V; Protti A; Maniscalco GT; Salemi G; Pesci I; Aguglia U; Lepore V; Filippi M; Trojano M; Amato MP;
JAMA Neurol; 2024 Jan; 81(1):50-58. PubMed ID: 38010712
[TBL] [Abstract][Full Text] [Related]
9. Progression Independent of Relapse Activity in Multiple Sclerosis: Closer to Solving the Pathologic Puzzle.
Tur C; Rocca MA
Neurology; 2024 Jan; 102(1):e207936. PubMed ID: 38165383
[TBL] [Abstract][Full Text] [Related]
10. Detecting ongoing disease activity in mildly affected multiple sclerosis patients under first-line therapies.
Masanneck L; Rolfes L; Regner-Nelke L; Willison A; Räuber S; Steffen F; Bittner S; Zipp F; Albrecht P; Ruck T; Hartung HP; Meuth SG; Pawlitzki M
Mult Scler Relat Disord; 2022 Jul; 63():103927. PubMed ID: 35700670
[TBL] [Abstract][Full Text] [Related]
11. Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study.
Portaccio E; Bellinvia A; Fonderico M; Pastò L; Razzolini L; Totaro R; Spitaleri D; Lugaresi A; Cocco E; Onofrj M; Di Palma F; Patti F; Maimone D; Valentino P; Confalonieri P; Protti A; Sola P; Lus G; Maniscalco GT; Brescia Morra V; Salemi G; Granella F; Pesci I; Bergamaschi R; Aguglia U; Vianello M; Simone M; Lepore V; Iaffaldano P; Filippi M; Trojano M; Amato MP
Brain; 2022 Aug; 145(8):2796-2805. PubMed ID: 35325059
[TBL] [Abstract][Full Text] [Related]
12. Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis.
Cagol A; Schaedelin S; Barakovic M; Benkert P; Todea RA; Rahmanzadeh R; Galbusera R; Lu PJ; Weigel M; Melie-Garcia L; Ruberte E; Siebenborn N; Battaglini M; Radue EW; Yaldizli Ö; Oechtering J; Sinnecker T; Lorscheider J; Fischer-Barnicol B; Müller S; Achtnichts L; Vehoff J; Disanto G; Findling O; Chan A; Salmen A; Pot C; Bridel C; Zecca C; Derfuss T; Lieb JM; Remonda L; Wagner F; Vargas MI; Du Pasquier R; Lalive PH; Pravatà E; Weber J; Cattin PC; Gobbi C; Leppert D; Kappos L; Kuhle J; Granziera C
JAMA Neurol; 2022 Jul; 79(7):682-692. PubMed ID: 35575778
[TBL] [Abstract][Full Text] [Related]
13. Contribution of relapse-associated worsening to overall disability accrual in patients with relapsing-onset multiple sclerosis: A mediation analysis.
Chen B; Ji SQ; Shen F; Tian DS; Bu BT
Mult Scler Relat Disord; 2022 Mar; 59():103555. PubMed ID: 35093839
[TBL] [Abstract][Full Text] [Related]
14. Exploring miRNAs' Based Modeling Approach for Predicting PIRA in Multiple Sclerosis: A Comprehensive Analysis.
Gosetti di Sturmeck T; Malimpensa L; Ferrazzano G; Belvisi D; Leodori G; Lembo F; Brandi R; Pascale E; Cattaneo A; Salvetti M; Conte A; D'Onofrio M; Arisi I
Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928049
[TBL] [Abstract][Full Text] [Related]
15. Association of Early Progression Independent of Relapse Activity With Long-term Disability After a First Demyelinating Event in Multiple Sclerosis.
Tur C; Carbonell-Mirabent P; Cobo-Calvo Á; Otero-Romero S; Arrambide G; Midaglia L; Castilló J; Vidal-Jordana Á; Rodríguez-Acevedo B; Zabalza A; Galán I; Nos C; Salerno A; Auger C; Pareto D; Comabella M; Río J; Sastre-Garriga J; Rovira À; Tintoré M; Montalban X
JAMA Neurol; 2023 Feb; 80(2):151-160. PubMed ID: 36534392
[TBL] [Abstract][Full Text] [Related]
16. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G
Cochrane Database Syst Rev; 2013 Jun; (6):CD008933. PubMed ID: 23744561
[TBL] [Abstract][Full Text] [Related]
17. Using the Progression Independent of Relapse Activity Framework to Unveil the Pathobiological Foundations of Multiple Sclerosis.
Ciccarelli O; Barkhof F; Calabrese M; De Stefano N; Eshaghi A; Filippi M; Gasperini C; Granziera C; Kappos L; Rocca MA; Rovira À; Sastre-Garriga J; Sormani MP; Tur C; Toosy AT;
Neurology; 2024 Jul; 103(1):e209444. PubMed ID: 38889384
[TBL] [Abstract][Full Text] [Related]
18. Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS.
Cagol A; Benkert P; Melie-Garcia L; Schaedelin SA; Leber S; Tsagkas C; Barakovic M; Galbusera R; Lu PJ; Weigel M; Ruberte E; Radue EW; Yaldizli Ö; Oechtering J; Lorscheider J; D'Souza M; Fischer-Barnicol B; Müller S; Achtnichts L; Vehoff J; Disanto G; Findling O; Chan A; Salmen A; Pot C; Bridel C; Zecca C; Derfuss T; Lieb JM; Remonda L; Wagner F; Vargas MI; Du Pasquier RA; Lalive PH; Pravatà E; Weber J; Cattin PC; Absinta M; Gobbi C; Leppert D; Kappos L; Kuhle J; Granziera C
Neurology; 2024 Jan; 102(1):e207768. PubMed ID: 38165377
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Accuracy of NEDA-3 in Long-term Outcomes of Multiple Sclerosis.
Prosperini L; Ruggieri S; Haggiag S; Tortorella C; Pozzilli C; Gasperini C
Neurol Neuroimmunol Neuroinflamm; 2021 Nov; 8(6):. PubMed ID: 34373345
[TBL] [Abstract][Full Text] [Related]
20. Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression.
Portaccio E; Betti M; De Meo E; Addazio I; Pastò L; Razzolini L; Totaro R; Spitaleri D; Lugaresi A; Cocco E; Onofrj M; Di Palma F; Patti F; Maimone D; Valentino P; Torri Clerici V; Protti A; Ferraro D; Lus G; Maniscalco GT; Brescia Morra V; Salemi G; Granella F; Pesci I; Bergamaschi R; Aguglia U; Vianello M; Simone M; Lepore V; Iaffaldano P; Comi G; Filippi M; Trojano M; Amato MP;
J Neurol; 2024 May; ():. PubMed ID: 38805052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
